| Liu, Jin |
NCT06203431: A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET-26) for the Induction of General Anesthesia in Elective Surgery Subjects |
|
|
| Recruiting | 3 | 270 | RoW | ET-26, Etomidate Injectable Emulsion | Ahon Pharmaceutical Co., Ltd. | Anesthesia Induction | 04/24 | 06/24 | | |
NCT03193710: The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved |
|
|
| Recruiting | N/A | 260 | RoW | Propofol, Diprivan, Sevoflurane, Abbvie, Remifentanil, YiChang HumanWell Pharmaceutical Co.，LTD. China | Guizhi Du | Colorectal Cancer Metastatic, Survival Rate, General Anesthetics Toxicity, Lymphocyte Destruction, Molecular Mechanism of Pharmacological Action | 10/18 | 10/23 | | |
| Recruiting | N/A | 300 | RoW | Dual-emission X-ray Absorptiometry | Fifth Affiliated Hospital, Sun Yat-Sen University | Degeneration of Spine and Osteoarticular | 07/22 | 12/22 | | |
NCT05034601: ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure |
|
|
| Completed | N/A | 68 | RoW | ESPB group, Erector spinae plane block, TPVB group, Thoracic paravertebral block | West China Hospital | Nerve Block, Analgesia, Pectus Excavatum | 03/23 | 03/23 | | |
| Wang, Ziqiang |
TNTCRT, NCT03177382: Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors |
|
|
| Recruiting | 3 | 458 | RoW | Total neoadjuvant treatment, TNT, concurrent chemoradiotherapy, CRT, TME, Adjuvant chemotherapy | West China Hospital | Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors | 05/21 | 05/23 | | |
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
|
|
| Recruiting | 3 | 688 | RoW | Radical colectomy, HIPEC, Systemic chemotherapy | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University | Colorectal Cancer | 04/24 | 04/26 | | |
COPEC, NCT04922853: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer |
|
|
| Recruiting | 3 | 554 | RoW | Capox chemotherapy | West China Hospital, The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Beijing Cancer Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd. | Rectal Cancer, Neoadjuvant Chemotherapy | 12/24 | 12/26 | | |
| Recruiting | 2 | 60 | RoW | FOLFOXIRI, XELOX | West China Hospital, GeneCast Biotechnology Co., Ltd. | Colon Cancer | 12/25 | 12/26 | | |
NCT06172049: Incidence of Colorectal Cancer in Southwest China: Based on SCC Database |
|
|
| Completed | N/A | 5838 | RoW | treatment | West China Hospital | Colorectal Cancer | 12/17 | 10/23 | | |
NCT03826862: Lateral Lymph Node Dissection for Middle-low Rectal Cancer |
|
|
| Recruiting | N/A | 30 | RoW | CT three-dimensional reconstruction | Ziqiang Wang,MD | Rectal Cancer | 12/20 | 12/22 | | |
NCT03930082: Frailty Assessment of Patients With Gastrointestinal Surgery |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Frailty Index Scale | Ziqiang Wang,MD | Gastrointestinal Disease, Frail Elderly Syndrome | 01/21 | 01/21 | | |
NCT06146946: Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) |
|
|
| Not yet recruiting | N/A | 1384 | RoW | Dissection of the No.253 lymph node, Omitting the dissection of the No.253 lymph node | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, China-Japan Friendship Hospital, Chinese PLA General Hospital, Ruijin Hospital, Fudan University, West China Hospital, Peking University Cancer Hospital & Institute | Rectal Cancer | 12/26 | 12/29 | | |
NCT05923255: LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer |
|
|
| Recruiting | N/A | 568 | RoW | LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）, TRH（Traditional Laparoscopic Right Hemicolectomy） | Zhejiang University | Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer | 05/26 | 05/31 | | |
NCT04635488: Prediction Model for Lateral Lymph Node Metastasis |
|
|
| Recruiting | N/A | 200 | RoW | lateral lymph node dissection | West China Hospital | Rectal Cancer | 06/21 | 12/22 | | |
NCT04646915: Evaluation of Short-term Outcomes of Day Surgery for Patients With CuRC |
|
|
| Enrolling by invitation | N/A | 120 | RoW | Day surgery | West China Hospital | Colorectal Cancer | 12/21 | 02/22 | | |
NCT05552170: Evaluation of Short-term Outcomes of Ambulatory Loop Ileostomy Reversal |
|
|
| Recruiting | N/A | 216 | RoW | day-case surgery | West China Hospital | Surgery, Fast Recovery Surgery | 07/25 | 08/25 | | |
| Zhang, Ming |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
NCT05297292: A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD |
|
|
| Recruiting | 2/3 | 433 | RoW | MW02, Lucentis, ranibizumab | Mabwell (Shanghai) Bioscience Co., Ltd. | Wet Age-related Macular Degeneration | 05/23 | 06/24 | | |
| Completed | 1/2 | 60 | RoW | 2.5mg of BAT5906, 4.0mg of BAT5906 | Bio-Thera Solutions | Diabetic Macular Edema | 11/23 | 11/23 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
| Recruiting | N/A | 192 | RoW | magnetic resonance image (MRI), serum | First Affiliated Hospital Xi'an Jiaotong University, NO.215 Hospital of Shaanxi Nuclear Industry, Baoji Zhongxin Hospital, Taihe Hospital | End Stage Renal Disease | 12/22 | 12/22 | | |
NCT05758623: Mg-containing Biodegradable Polymer Bone Repair Material |
|
|
| Recruiting | N/A | 176 | RoW | Device | Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Chinese University of Hong Kong | Bone Deformity | 04/23 | 03/24 | | |
| Recruiting | N/A | 60 | RoW | Scanning with magnetic resonance imaging | First Affiliated Hospital Xi'an Jiaotong University | Hemifacial Spasm, Magnetic Resonance Imaging | 06/24 | 12/24 | | |
| Recruiting | N/A | 80 | RoW | physiotherapy and maxillary traction, massage therapy | First Affiliated Hospital Xi'an Jiaotong University | Neck Pain | 12/26 | 12/27 | | |
NCT06228196: Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China |
|
|
| Recruiting | N/A | 150 | RoW | Simultaneous cortico-spinal magnetic resonance imaging, Serum | First Affiliated Hospital Xi'an Jiaotong University | BPPV, Vertigo, Vertigo, Peripheral | 06/26 | 09/26 | | |
| Active, not recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
| Recruiting | N/A | 100 | Europe, Canada, US | Edwards APTURE transcatheter shunt system, Sham procedure | Edwards Lifesciences | Heart Failure | 01/26 | 07/30 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/27 | 12/31 | | |
NCT05090007: Imaging of Injury Mechanism and Interaction of Intestinal Bacteria in Children With Mild Traumatic Brain Injury |
|
|
| Recruiting | N/A | 300 | RoW | magnetic resonance image, gut microbiota | First Affiliated Hospital Xi'an Jiaotong University, School of Life Science and Technology, Xi'an Jiaotong University, The Second Affiliated Hospital and Yuying Childern's Hospital of Wenzhou Medical University | MTBI - Mild Traumatic Brain Injury | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 2000 | RoW | | China-Japan Friendship Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, First Hospital of China Medical University, Henan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Sichuan University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China | Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis | 07/28 | 07/28 | | |
NCT05108909: Rapid Diagnosis and Prognosis Recognition of Imaging and Biomarkers in Mild to Moderate Traumatic Brain Injury |
|
|
| Recruiting | N/A | 800 | RoW | MRI, CT, and serum biomarkers | First Affiliated Hospital Xi'an Jiaotong University, School of Life Science and Technology, Xi'an Jiaotong University, Second Affiliated Hospital of Wenzhou Medical University, Central South University, Xijing Hospital | MTBI - Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury | 08/25 | 08/25 | | |
NCT05494190: The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 111 | RoW | Docetaxel, Cisplatin, Capecitabine, Concomitant chemoradiotherapy, Surgery | Eye & ENT Hospital of Fudan University, Shandong Provincial Hospital, Harbin Medical University Third Affiliated Hospital | Hypopharyngeal Carcinoma | 11/25 | 11/25 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
NCT05745805: Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China |
|
|
| Recruiting | N/A | 600 | RoW | Simultaneous cortico-spinal magnetic resonance imaging, Serum | First Affiliated Hospital Xi'an Jiaotong University, Nuclear 215 Hospital of Shaanxi Province, Yanan Traditional Chinese Medicine Hospital, Shangluo Central Hospital, Xian QinHuang Hospital, Yulin No.2 Hospital, Hanzhong Central Hospital, Ankang Central Hospital, Baoji High-tech Hospital | COVID-19, Post-COVID-19 Syndrome, Acute COVID-19, Post-Acute COVID-19 | 06/26 | 09/26 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
| Lu, Fang |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT06300476: Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1) |
|
|
| Active, not recruiting | 1/2 | 9 | RoW | JWK006 | West China Hospital | Stargardt Disease 1 | 12/26 | 12/29 | | |
NCT05832684: Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy |
|
|
| Active, not recruiting | 1/2 | 24 | RoW | ZVS101e, rAAV2/8-hCYP4V2, rAAV8-hCYP4V2, AAV8-hCYP4V2 | Chigenovo Co., Ltd | Bietti's Crystalline Dystrophy | 12/24 | 12/28 | | |
NCT06345898: Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS) |
|
|
| Recruiting | 1 | 18 | RoW | JWK002 | West China Hospital | X Linked Retinoschisis | 12/26 | 12/29 | | |
| Liu, Fei |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Liu, Jiyan |
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation |
|
|
| Recruiting | 2 | 30 | RoW | HLX208 | Shanghai Henlius Biotech | Advanced Melanoma | 08/23 | 08/24 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 06/25 | 06/25 | | |
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | 06/25 | 06/25 | | |
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 156 | RoW | JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection | Shanghai Junshi Bioscience Co., Ltd. | Melanoma, Renal Carcinoma, Urothelial Carcinoma | 02/24 | 08/24 | | |
| Wu, Hong |
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 4 | 334 | RoW | Kanglaite Injection+Chemotherapy, Chemotherapy | Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences | NSCLC | 03/22 | 05/22 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT06558227: Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | ZG005 for Injection, ZG005, Bevacizumab, Avastin, Sintilimab, 达攸同 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Hepatocellular Carcinoma | 09/26 | 10/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT06219096: Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection |
|
|
| Recruiting | N/A | 100 | RoW | NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration, NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration | West China Hospital, Nanjing Chia-Tai Tianqing Pharmaceutical Company | Malignant Tumor of Liver, Randomized Controlled Trial | 12/26 | 12/28 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Peng, Xingchen |
NCT04414566: Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 562 | RoW | gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, GP;TPF, IMRT, IMRT and concurrent cisplatin | West China Hospital | Nasopharyngeal Carcinoma | 05/22 | 05/25 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT05805800: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV |
|
|
| Recruiting | 3 | 238 | RoW | 5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone | Xingchen Peng | Chemotherapy-induced Nausea and Vomiting | 03/24 | 03/25 | | |
NCT06663956: A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management |
|
|
| Recruiting | 3 | 100 | RoW | a patient self-reporting applet | West China Hospital | Cancer Pain | 10/26 | 10/26 | | |
NCT04316039: Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery |
|
|
| Recruiting | 2/3 | 250 | RoW | Temozolomide, intensity modulated radiation therapy | West China Hospital | Low-grade Glioma | 04/23 | 12/28 | | |
| Completed | 2 | 160 | RoW | Streptococcus salivarius K12, OralBiotic BLIS K12 (NOW Foods, USA), Streptococcus salivarius K12 simulants | West China Hospital, Project funding | Head and Neck Squamous Cell Carcinoma | 11/22 | 11/22 | | |
NCT04318730: Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma |
|
|
| Recruiting | 2 | 21 | RoW | Camrelizumab, Apatinib | West China Hospital | Adrenocortical Carcinoma | 12/23 | 04/25 | | |
| Recruiting | 2 | 28 | RoW | Nab-paclitaxel, Albumin-bound paclitaxel, Abraxane, Cisplatin, CDDP, Tislelizumab, BGB-A317, Afatinib | West China Hospital | Head and Neck Squamous Cell Carcinoma | 08/23 | 08/24 | | |
| Recruiting | 2 | 23 | RoW | Tislelizumab, BGB-A317, Afatinib | West China Hospital | Head and Neck Cancer | 08/23 | 08/24 | | |
NCT05659186: PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, BGB-A317, Anlotinib, AL3818, Radiotherapy | West China Hospital | Thyroid Cancer | 12/24 | 12/25 | | |
NCT06804850: A Randomized Controlled Study Comparing Low-dose Radiotherapy Combined With Target-free Therapy Versus Target-free Therapy Alone in Neoadjuvant Treatment for Resectable Head and Neck Squamous Cell Carcinoma. |
|
|
| Not yet recruiting | 2 | 98 | RoW | Tislelizumab, Immunotherapy, Afatinib, Targeted therapy, Low dose radiotherapy, Radiotherapy | West China Hospital | Head and Neck Cancer | 06/26 | 06/26 | | |
NCT05299203: BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) |
|
|
| Not yet recruiting | 1a/1b | 18 | NA | Sapropterin dihydrochloride tablets | West China Hospital | Head and Neck Squamous Cell Carcinoma | 12/22 | 05/23 | | |
NCT05714748: Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors |
|
|
| Recruiting | 1 | 9 | RoW | EBV mRNA vaccine | West China Hospital | Malignant Tumors | 01/24 | 01/25 | | |
NCT05707910: Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 9 | RoW | EBV immunological agent, Toripalimab 240mg | West China Hospital | Malignant Tumor | 01/24 | 01/25 | | |
NCT05738447: Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 9 | RoW | HBV mRNA vaccine | West China Hospital | Liver Cancer, Hepatocellular Carcinoma | 01/24 | 01/25 | | |
NCT06332664: Early Nutrition Intervention for M1 Stage Cancer Patients |
|
|
| Recruiting | 1 | 194 | RoW | Early Nutrition Intervention | Xingchen Peng | Nutrition, Cancer Metastatic | 01/25 | 07/25 | | |
NCT06494189: Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma |
|
|
| Recruiting | 1 | 29 | RoW | Tislelizumab, Afatinib, Low dose radiotherapy | West China Hospital | Head and Neck Cancer | 07/25 | 12/25 | | |
NCT06519552: A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I |
|
|
| Recruiting | 1 | 6 | RoW | JWK008 Single intravenous infusion administration | West China Hospital | Mucopolysaccharidosis Type I | 06/26 | 06/29 | | |
NCT06666153: Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases |
|
|
| Not yet recruiting | 1 | 27 | RoW | EBV immunological agent | West China Hospital | CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs | 12/25 | 12/26 | | |
NCT06080984: The Application of Novel Oncolytic Virus in Late Stage Solid Tumors |
|
|
| Recruiting | 1 | 24 | RoW | Oncolytic Virus SDJ001, Oncolytic Virus YD06-1 | West China Hospital | Malignant Tumor | 10/24 | 10/25 | | |
NCT06741982: A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus |
|
|
| Recruiting | 1 | 21 | RoW | Lysogenic HSV virus., Biological agent, Tislelizumab, Immunotherapy, Afatinib, Targeted therapy | West China Hospital | HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy | 12/26 | 12/26 | | |
NCT06114056: A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD) |
|
|
| Recruiting | 1 | 6 | RoW | JWK007 Single intravenous infusion administration | West China Hospital | Duchenne Muscular Dystrophy | 06/25 | 12/28 | | |
NCT06272617: Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer |
|
|
| Recruiting | N/A | 138 | RoW | verum acupuncture, sham acupuncture | West China Hospital, West China Fourth Hospital, Sichuan University | Malignant Tumor of Head and/or Neck, Radiotherapy; Complications | 07/24 | 07/25 | | |
NCT05828004: Effect of Whole-Course Multidisciplinary Care Intervention on Patients With Head and Neck Carcinoma |
|
|
| Completed | N/A | 226 | RoW | Whole-Course Multidisciplinary Care Intervention | West China Hospital | Head and Neck Carcinoma | 10/23 | 12/23 | | |
NCT06390176: Lactobacillus Rhamnosus GG Alleviates Oral Mucositis in Patients Undergoing Radiotherapy |
|
|
| Recruiting | N/A | 132 | RoW | Lactobacillus rhamnosus GG powder, Placebo-containing tablets, Radiotherapy | West China Hospital | Oral Mucositis | 03/25 | 03/25 | | |
NCT06285591: Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors |
|
|
| Recruiting | N/A | 160 | RoW | Lactobacillus Reuteri Tablets, Placebo-containing tablets, Radiotherapy | West China Hospital, The General Hospital of Western Theater Command | Oral Mucositis (Ulcerative) Due to Radiation | 12/24 | 12/24 | | |
NCT06484166: Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer . |
|
|
| Not yet recruiting | N/A | 132 | NA | Fullerene cream, Trolamine (Biafine) | West China Hospital | Radiation Dermatitis | 12/24 | 04/25 | | |
NCT06690346: Systematic Oral Education for Prevention of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer |
|
|
| Recruiting | N/A | 150 | RoW | Systematic oral health education, Routine oral health education | West China Hospital, West China Fourth Hospital, Sichuan University | Malignant Tumor of Head And/or Neck, Radiotherapy; Complications | 08/25 | 08/26 | | |
NCT06674499: Development and Evaluation of a Self-Management Model for Cancer Rehabilitation |
|
|
| Recruiting | N/A | 144 | RoW | Self-help rehabilitation model, Conventional rehabilitation model | Xingchen Peng | Head and Neck Cancer, Rehabilitation, Psychotherapy | 12/26 | 06/27 | | |
